Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MA.5 - Cooperative Clinical Trial of Intensive CEF versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients With Histologically Involved Axillary Nodes

Spears M, Yousif F, Lyttle N, Boutros PC, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JM. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. Oncotarget 6: 31693-701, 2015.[]=5562&path[]=13043

Canadian Cancer Trials Group PA.3 - A Randomized Placebo Controlled Study of OSI-774 Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Peron J, Roy P, Ding K, Parulekar WR, Roche L, Buyse M. Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. Br J Cancer 112: 971-6, 2015.

Canadian Cancer Trials Group GA.1 - A Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer (TOPGEAR)

Leong T, Smithers B, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/Canadian Cancer Trials Group). BMC Cancer 15: 532, 2015.

Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Gr?goire V, van Herk M, Lee A, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, Canadian Cancer Trials Group, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology 117: 83-90, 2015.